Global (68M) cardiomyopathies market set to reach $9.63 bn by 2031: GlobalData
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
Subscribe To Our Newsletter & Stay Updated